Biomarkers Identified for Possible Blood Test to Predicting Suicide Risk

Niculescu III, MD, PhD, associate professor of psychiatry and medical neuroscience at the IU School of Medicine, and director of the laboratory of neurophenomics at the Institute of Psychiatric Research at the IU School of Medicine, stated that he believes the findings offer a first proof of principle for a test that could provide an early warning of somebody being at higher risk for an impulsive suicide act.

“Suicide is a big problem in psychiatry. It’s a big problem in the civilian realm, it’s a big problem in the military realm, and there are no objective markers,” said Dr. Niculescu. “There are people who will not reveal they are having suicidal thoughts when you ask them, who then commit it and there’s nothing you can do about it. We need better ways to identify, intervene, and prevent these tragic cases,” he said.

Dr. Niculescu and his colleagues, over a three-year period, monitored a large group of patients diagnosed with bipolar disorder, completing interviews and taking blood samples every three to six months. The researchers conducted a range of analyses of the blood of a subset of participants who reported a dramatic shift from no suicidal thoughts to strong suicidal ideation. They identified differences in gene expression between the “low” and “high” states of suicidal thoughts and subjected those findings to a system of genetic and genomic analysis called convergent functional genomics that identified and prioritized the best markers by cross-validation with other lines of evidence.

The researchers discovered that the marker SAT1 and a series of other markers provided the strongest biologic “signal” tied to suicidal thoughts. Next, to confirm their findings, working with the local coroner’s office, they analyzed blood samples from suicide victims and discovered that some of same top markers were considerably elevated.

Lastly, the researchers analyzed blood test findings from two additional groups of patients and found that high blood levels of the biomarkers were correlated with future suicide-related hospitalizations, as well as hospitalizations that had occurred before the blood tests. “This suggests that these markers reflect more than just a current state of high risk, but could be trait markers that correlate with long term risk,” said Dr. Niculescu.

Although convinced in the biomarkers validity, Dr. Niculescu noted that a limitation is that the research subjects were all male. “There could be gender differences,” he said. “We would also like to conduct more extensive, normative studies, in the population at large.”

Dr. Niculescu and colleagues, in addition to extending the research to females to see if the same or other markers come into play, plan to conduct research among other groups, including individuals who have less impulsive, more methodical, and planned subtypes of suicide. However, Dr. Niculescu said, “These seem to be good markers for suicidal behavior in males who have bipolar mood disorders or males in the general population who commit impulsive violent suicide. In the future we want to study and assemble clinical and sociodemographic risk factors, along with our blood tests, to increase our ability to predict risk. Suicide is complex: in addition to psychiatric and addiction issues that make people more vulnerable, there are existential issues related to lack of satisfaction with one’s life, lack of hope for the future, not feeling needed, and cultural factors that make suicide seem like an option.”

Dr. Niculescu reported that he hopes such biomarkers, combined with other approaches, including neuropsychologic testing and sociodemographic specifications currently in development by his group, ultimately can help identify people who are at risk, leading to preemptive intervention, counseling, and saved lives. “Over a million people each year worldwide die from suicide and this is a preventable tragedy.”

Related Links:
Indiana University School of Medicine